



(86) Date de dépôt PCT/PCT Filing Date: 2007/07/24
(87) Date publication PCT/PCT Publication Date: 2008/02/07
(85) Entrée phase nationale/National Entry: 2009/01/14
(86) N° demande PCT/PCT Application No.: GB 2007/002789
(87) N° publication PCT/PCT Publication No.: 2008/015384
(30) Priorité/Priority: 2006/08/04 (US60/821,553)


(51) Cl.Int./Int.Cl. *G06F 19/00* (2006.01)

(71) Demandeur/Applicant:
LONZA BIOLOGICS PLC, GB

(72) Inventeurs/Inventors:
KOHLHOFF, KAI J., GB;
ZURDO, JESUS, GB;
VENDRUSCOLO, MICHELE, GB

(74) Agent: SMART & BIGGAR

(54) Titre : PROCÉDE PERMETTANT DE PREDIRE L'AGREGATION D'UNE PROTEINE ET DE CONCEVOIR DES INHIBITEURS D'AGREGATION
(54) Title: METHOD FOR PREDICTING PROTEIN AGGREGATION AND DESIGNING AGGREGATION INHIBITORS



(57) **Abrégé/Abstract:**

The present invention provides methods of predicting protein aggregation and designing aggregation inhibitors. One such method for predicting potential protein aggregation inhibiting peptide sequences, includes the steps of: a) identifying a peptide sequence



(57) **Abrégé(suite)/Abstract(continued):**

forming at least part of an aggregation region in a target protein; b) testing whether said peptide sequence forms part of a β -sheet; c) if a positive result is achieved in step b), extracting the adjacent strands of that sheet; d) identifying residues in the adjacent strands to said peptide sequence whose side chains interact with said peptide sequence, those residues forming a potential protein aggregation inhibiting peptide sequence. The present invention also provides methods of designing compounds using the residues identified in the above method; compounds produced by the methods and computer programs for carrying out the above methods.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
7 February 2008 (07.02.2008)

PCT

(10) International Publication Number
WO 2008/015384 A1(51) International Patent Classification:
G06F 19/00 (2006.01)(21) International Application Number:
PCT/GB2007/002789

(22) International Filing Date: 24 July 2007 (24.07.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/821,553 4 August 2006 (04.08.2006) US(71) Applicant (for all designated States except US): **LONZA BIOLOGICS PLC** [GB/GB]; 228 Bath Road, Slough, Berkshire SL1 4DX (GB).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **KOHLHOFF, Kai, J.** [DE/GB]; Darwin College, Silver Street, Cambridge, Cambridgeshire CB3 9EU (GB). **ZURDO, Jesus**[ES/GB]; Lonza Biologics plc, Babraham Research Campus, Cambridge CB22 3AT (GB). **VENDRUSCOLO, Michele** [IT/GB]; Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, Cambridgeshire CB2 1EW (GB).(74) Agents: **HODSDON, Stephen** et al.; Mewburn Ellis LLP, York House, 23 Kingsway, London, Greater London WC2B 6HP (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: METHOD FOR PREDICTING PROTEIN AGGREGATION AND DESIGNING AGGREGATION INHIBITORS

Flow chart of peptide search process



(57) Abstract: The present invention provides methods of predicting protein aggregation and designing aggregation inhibitors. One such method for predicting potential protein aggregation inhibiting peptide sequences, includes the steps of: a) identifying a peptide sequence forming at least part of an aggregation region in a target protein; b) testing whether said peptide sequence forms part of a β -sheet; c) if a positive result is achieved in step b), extracting the adjacent strands of that sheet; d) identifying residues in the adjacent strands to said peptide sequence whose side chains interact with said peptide sequence, those residues forming a potential protein aggregation inhibiting peptide sequence. The present invention also provides methods of designing compounds using the residues identified in the above method; compounds produced by the methods and computer programs for carrying out the above methods.

WO 2008/015384 A1

WO 2008/015384 A1

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

(48) Date of publication of this corrected version:

15 May 2008

(15) Information about Correction:

see Notice of 15 May 2008

**Method for predicting protein aggregation and designing
aggregation inhibitors**

The present invention relates to methods of predicting protein aggregation and designing aggregation inhibitors. It is particularly, but not exclusively, concerned with methods which assist in the design of compounds for stabilisation of proteins against aggregation, thus potentially increasing the shelf-life of proteins, decreasing immunogenicity of proteins and increasing yields in in vitro translation systems.

BACKGROUND TO THE INVENTION

Deposits of misfolded proteins in cells or in intracellular space are found to play a role in a number of severe medical disorders, among which are diseases such as Alzheimer's, Parkinson's, and type-2 diabetes. The costs incurred by the health care systems worldwide for treating those medical conditions are massive, as is the impact onto the lives of those that are affected and their families.

The number of cases is likely to increase steadily as life expectancy rises. To address this growing problem, new therapies are being developed based on interfering at early stages with the ability of proteins to form aggregates.

The typical life cycle of a protein in the cell begins with synthesis of the polypeptide at the ribosome and continues from an initially unfolded state via a folding pathway, which might involve one or several folding

intermediates, to the biologically-active native state of the protein. For most proteins, this native state corresponds to a closely folded conformation, although some exceptions exist, one of which is α -synuclein, which is natively unfolded (Uversky VN (2002) *Natively unfolded proteins: A point where biology waits for physics*, Protein Sci. 11:739-756). The life cycle ends with denaturation and degradation.

The cell possesses sophisticated quality control mechanisms that assist the folding process of the protein. The first of these is the ribosome itself. In the second, the protein is supported by heat shock proteins and chaperones that act as catalyst or promoter to fold a protein in the correct way, or to refold misfolded proteins (Evans MS, Clarke TF IV, Clark PL (2005) *Conformations of Co-Translational Folding Intermediates*, Prot, Pept. Let.12(2): 189-195).

In the case that refolding fails, misfolded proteins are processed by the ubiquitin-proteasome system. In a first step, ubiquitin is being attached to faulty structures. These tags mark the polypeptide chain for degradation and this task is fulfilled by the proteasome. A more detailed description of folding and misfolding processes can be found in Dobson CM (2003) *Protein folding and misfolding*, Nature 426: 884-890 and Vendruscolo M, Zurdo J, MacPhee CE, Dobson CM (2003) *Protein folding and misfolding: a paradigm of self-assembly and regulation in complex biological systems*, Phil. Trans. R. Soc. Lond. A 361: 1205-1222).

However, the quality control of the cell can fail for a variety of reasons, leading to accumulation of misfolded proteins. These proteins can then aggregate forming dense structures called amyloid fibrils with a core region consisting of continuous assemblies of β -sheets (Dobson CM (2005) *Prying into prions*, Nature 435: 747-749).

In living tissue, protein deposition (often in the form of amyloid aggregates) is frequently associated with a variety of diseases, many of which are age related. For example, these diseases include neurodegenerative diseases such as Parkinson's, Alzheimer's and spongiform encephalopathies, as well as systemic (such as immunoglobulin light chain or transthyretin amyloidoses) and peripheral tissue disorders (such as type-2 diabetes). In humans, more than 30 different disorders are known to be associated with protein deposition.

Particularly in the developed world, where the life expectancy continues to rise steadily, the ever-growing number of people affected with those diseases poses unprecedented and increasingly severe problems to society.

It is estimated that in the United States alone about 4.5 million people were affected by Alzheimer's disease in 2000, and the number of cases might rise to 16 million by 2050 (Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) *Alzheimer Disease in the U.S. Population: Prevalence Estimates Using the 2000 Census*, Arch. Neurol. 60: 1119-1122). The risk of people being affected with this neurodegenerative disease is estimated to be as high as 1 in 10 for people over 60 years of age and almost 1

in 2 for those over 85 (Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO (1989) *Prevalence of Alzheimer's Disease in a Community Population of Older Persons. Higher than Previously Reported*, Jama 262: 2551-2556). The impact onto the health systems is immense, and some authors predict that neurodegenerative diseases could become the leading cause of death (Lozano AM, Kalia SK (2005) *New Movements in Parkinsons's*, Sci. Am., 291(1): 58-65).

Furthermore, the propensity of biomolecules to form aggregates in solution has always been one of the major problems in drug design. Therapeutic molecules must be both soluble as well as reactive and should not form aggregates when administered in relatively high concentrations or stored over long periods of time. In many cases, finding conditions in which such polypeptides are sufficiently stable proves to be time consuming and costly, and sometimes even impossible with currently available methods. Finding ways to interfere with the folding process in order to impede the formation of aggregates can therefore improve the efficiency of drug development.

SUMMARY OF THE INVENTION

Therefore, to preferably assist in the addressing of the above issues, it is desirable to be able to design compounds that interact with a pathological protein, or with a therapeutic molecule in solution, so that the compound competitively binds to and blocks the most important sites driving the aggregation process. One of the approximations to achieve this goal would involve the

design of peptide-derived molecules that would interfere with the aggregation process.

Accordingly, at its broadest, an aspect of the present invention provides a method of designing protein aggregation inhibiting peptides which involves identifying peptide sequences whose side chains would interact with an aggregation-prone region in a target protein.

A first aspect of the present invention provides a method for predicting potential protein aggregation inhibiting peptide sequences, including the steps of:

- a) identifying a peptide sequence forming at least part of an aggregation region in a target protein;
- b) testing whether said peptide sequence forms part of a β -sheet;
- c) if a positive result is achieved in step b), extracting the adjacent strands of that sheet;
- d) identifying residues in the adjacent strands to said peptide sequence whose side chains interact with said peptide sequence, those residues forming a potential protein aggregation inhibiting peptide sequence.

Preferably the step of testing is carried out on a plurality of heterologous proteins to the target protein. Accordingly, even where the aggregation region in the target protein does not form part of a β -sheet, appropriate peptide sequences can be identified from similar or identical sequences found in other proteins which do form part of a β -sheet.

This testing can be performed by using a database of protein structures, and preferably tests whether said

peptide sequence forms part of a β -sheet in any of the known protein structures present in that database. In embodiments of the invention, data from the Protein Data Bank (PDB) of the Research Collaboratory for Structural Bioinformatics (RCSB) is used, which contains a large number of experimental structures and theoretical models (Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) *The Protein Data Bank*, Nuc. Acids Res. 28: 235-242). As of 27 June 2005, there were 31639 structures in the PDB. However, other structural databases or databanks may be used.

The first step in predicting an aggregation inhibiting peptide is to identify one or more aggregation regions in the target protein, and the peptide sequences forming at least part of this region.

A preferred method of identifying this region is to use an amyloid aggregation profile. This theoretical method for the prediction of aggregation hotspots within polypeptide chains is described in DuBay KF, Pawar AP, Chiti F, Zurdo J, Dobson CM, Vendruscolo M (2004) *Prediction of the Absolute Aggregation Rates of Amyloidogenic Polypeptide Chains*, J. Mol. Biol. 341: 1317-1326 and in Pawar AP, DuBay KF, Zurdo J, Chiti F, Vendruscolo M, Dobson CM (2005) *Prediction of "aggregation-prone" and "aggregation-susceptible" regions in proteins associated with neurodegenerative diseases*, J. Mol. Biol. 350: 379-392. The method provides an algorithm that, based on a number of intrinsic properties of amino acids, can be used to calculate an amyloid aggregation propensity profile for any protein.

Once an amyloid aggregation profile has been obtained for the target protein, aggregation regions can be identified by considering the parts of the protein for which the aggregation propensity in the profile exceeds a predetermined amount (such as 1).

Alternatively or additionally, the aggregation regions can be identified by experimental measurements, for example by systematic mutation of each of the residues in a peptide or protein or fragment thereof, and synthesising fragments of such peptides or proteins or fragments and analysing their aggregation propensity in *in vitro* assays.

Preferably the step of testing includes the sub-steps of: identifying a group of proteins contained in a database of protein structures which contain related peptide sequences related to the peptide sequence forming at least part of an aggregation region in a target protein; and identifying within that group those proteins in which said related peptide sequences form part of a β -sheet.

In order to increase the probable number of hits (i.e. identified proteins in which the related peptide sequences form part of a β -sheet), the related peptide sequences preferably include the peptide sequence of interest and fragments of said peptide sequence.

Alternatively or additionally, to increase the probable number of hits, the related peptide sequences may include sequences which include conservative substitutions of one or more amino acids with the peptide sequence of interest.

In the context of this step, a conservative substitution is a substitution which preserves the aggregation properties of the amino acid being substituted. In particular, the conservative substitutes may be chosen on the basis of amino acids with aggregation propensities at pH 7.0 which are within 0.2 of each other. Alternatively or additionally, the conservative substitutes may be chosen on the basis of residues with similar properties (e.g. basic, acidic, hydrophobic, polar, aromatic).

More preferably the related peptide sequences include one or more of the above peptide sequences in both forward and reverse order.

In one embodiment of the present aspect, the sub-step of identifying a group of proteins contained in the database includes comparing the related peptide sequences with the residues contained in "SHEET" lines in a PDB file for the protein in question.

Alternatively or additionally, the sub-step of identifying a group of proteins contained in the database includes identifying those residues in the related peptide sequences that form hydrogen bonds with each other.

One method by which residues that form hydrogen bonds with each other may be identified is to calculate the Euclidean distance between each pair of residues which are at least three residues apart, with a hydrogen bond being assumed to form if that distance is less than 3.2 Angstrom, and more preferably if that distance is less than 3.075 Angstrom. In one embodiment, these Euclidean

distances are calculated using "ATOM" entries from the PDB file for the protein in question.

Preferably the method includes the further step of displaying the identified residue pairs that form hydrogen bonds with each other, and the hydrogen bonds formed.

In order to check the validity of the results from either of the above ways of identifying the group of proteins, the results from both methods may be used to cross-check the residues identified from the other method. Such cross-checks can alternatively or additionally be performed with other methods of identifying the group of proteins.

The method preferably includes the further step of displaying the residues identified in step d), and may also include the step of displaying information about the protein from which these residues are identified. This displaying may take the form of a 3-dimensional arrangement of the identified residues in the β -sheet.

Preferably, the method includes the further step of modifying the backbone of adjacent strands and sidechains to the potential protein aggregation inhibiting peptide sequence not directly participating in the interaction with said peptide sequence forming part of an aggregation region in the target protein, to maximise interaction with said peptide sequence and increase the potential aggregation inhibition properties of the potential aggregation inhibiting sequence.

Once one or more peptide sequences or "templates" have been identified, a peptide library can be designed and synthesised which introduces variability on the regions of the template not directly involved in the interaction with the aggregation region in question. This library could then be screened using proprietary biochemical aggregation and cytotoxicity assays to investigate changes in aggregation rates and toxicity of proteins in the presence of various compounds.

The library is preferably created by adding modifications to the candidate amino acid sequence(s) that improve properties such as stability and solubility.

A method as described herein may, for example comprise: e) synthesising a peptide library, the members of said peptide library comprising the residues identified in step d), and f) determining the binding affinity of the members of said library for the target protein.

One or more peptides may be identified within the library which binds to the target protein with high affinity relative to controls. Such peptides may be candidate protein aggregation inhibiting peptides.

A peptide found to bind to the target with high affinity may be isolated, purified and/or synthesised.

Peptide sequences which have been predicted or identified as described above may be screened for interference with cellular processes (i.e. toxicology). For example, a method may comprise: testing whether the residues identified in step d) above interact with one or more non-target proteins existing in the Protein Data Bank (or

any other protein database), preferably non-target proteins which could mediate essential cellular processes, such as metabolic pathways, ionic homeostasis structural proteins, proteins involved in response to stress, regulating gene expression, DNA repair, etc.

The step of testing may be carried out on a plurality of heterologous proteins to said target protein, preferably using a database of protein structures. Testing may, for example, be performed by identifying a group of proteins within the database which contain related peptide sequences which are related to the test peptide sequence; and identifying within the group those proteins in which the related peptide sequences interact with the residues identified in step d) above.

Candidate protein aggregation inhibiting peptide sequences may be identified which do not interact with proteins which mediate essential cellular processes.

The efficacy of a peptide sequence identified as described above may be determined in a model of a protein misfolding disease.

Models of protein misfolding diseases are well known in the art. Suitable models include cells which over-express an aggregation-prone protein, and transgenic animal models such as mouse or drosophila models which over-express an aggregation-prone and that might or not be exposed to other challenges, such as oxidative stress, etc.

For example, see:

Junn E, Mouradian MM, *Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine*, Neurosci Lett. 2002;320:146-50.

Lev N, Melamed E, Offen D, *Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage*, Neurosci Lett. 2006;399:27-32.

McGowan E, Eriksen J, Hutton M, *A decade of modeling Alzheimer's disease in transgenic mice*, Trends Genet. 2006; 22:281-9.

Whitworth AJ, Wes PD, Pallanck LJ, *Drosophila models pioneer a new approach to drug discovery for Parkinson's disease*, Drug Discov Today. 2006 Feb;11(3-4):119-26.

Aggregation-prone proteins include the following proteins, precursors or fragments of: α -synuclein (either wild type or any of the mutants associated to Parkinson's disease), huntingtin (as well as other proteins with expanded polyglutamine or polyalanine repeats), amyloid beta peptide (A β 42), Prion protein, Islet amyloid polypeptide (hIAPP) or amylin, Superoxyde Dismutase, Tau, alpha-1-antitrypsin and other serpins, lysozyme, vitronectin, crystallins, Fibrinogen alpha chain, Apolipoprotein AI, Cystatin C, Gelsolin, Lactoferrin, Keratoepithelin, Calcitonin, Atrial natriuretic factor, Prolactin, Keratin, Medin (or full-length lactadherin), Immunoglobulin light chains, Transthyretin (TTR), apo-serum amyloid A protein (SAA), Beta2-microglobulin, Immunoglobulin heavy chains, or any other protein associated with any protein misfolding disorder.

The ability of a peptide sequence identified as described above to perform one or more the following may be determined:

- i. stabilise a protein against aggregation;
- ii reduce the rate of loss of activity of a protein in storage;
- iii. decrease the aggregation-mediated immunogenicity of a protein;
- iv. increase the yields of proteins in *in vitro* translation systems;
- v. increase the stability in solution of a formulation for therapeutic use;
- vi. inhibit one or more cellular processes;
- vii. prevent oligomerisation or multimerisation of a protein.

Further aspects of the present invention provide methods of designing aggregation inhibitors to treat protein misfolding diseases using the residue(s) identified in step d) of the above first aspect; designing compounds for stabilising proteins (e.g. biopharmaceuticals, antibodies, enzymes, etc.) against aggregations in formulations, vehicles and other solutions using the identified residue(s); designing compounds to increase the shelf life of such proteins using the identified residue(s); designing compounds to decrease immunogenicity of proteins due to aggregation using the identified residue(s); and designing compounds to increase the yields of proteins in *in vitro* translation systems using the identified residue(s).

Another aspect of the present invention provides a computer program which, when run on a computer, performs the method of any of the above aspects.

Another aspect of the present invention provides a computer data carrier containing a computer program according to the previous aspect.

A further aspect of the present invention provides a computer arranged to perform the method of any one of the above method aspects. Preferably this computer is a general purpose computer which is arranged to access databases containing information on known proteins for use in obtaining the prediction. Such databases may be stored locally, e.g. on a hard disk drive or in a memory, but are preferably stored remotely and accessed over a communications link such as a network or the internet.

BRIEF DESCRIPTION OF THE DRAWINGS

Embodiments of the invention will now be described with reference to the accompanying drawings, in which:

Figure 1 shows the amyloid aggregation profiles of A β 42 and α -synuclein at pH 7;

Figure 2 shows the amyloid aggregation profile of a mutant of γ -crystallin D at pH 7;

Figure 3 shows the output of the PeptideSearch program for residues 1 to 8 of mutCRYD34-58;

Figure 4 shows a flow chart for the peptide search process;

Figure 5 shows extracts from the pdb_seqres.txt and ss.txt files obtained from the PDB;

Figure 6 shows the prediction of hydrogen bonds in three adjacent strand in a β -sheet;

Figure 7 show an example output from the program for predicting hydrogen bonds between residues;

Figure 8 shows a result summary for a hit in the peptide searching; and

Figure 9 shows aggregation propensity profiles for mutCRYD34-58, A β 42 and α -synuclein with indications of the positions at which short peptide matches were found in the PDB.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Embodiments of the present invention will be described below. The methodology of the present embodiment will be demonstrated on a mutant of γ -crystallin D (mutCRYD). For the purposes of illustration, two further proteins are also discussed: α -synuclein, which is involved in Parkinson's disease, and A β 42, which is associated with Alzheimer's disease.

mutCRYD is abundant in lens cells of the human eye. When misfolding, it can form aggregates that show up as cataracts leading to blurred vision or blindness (Héon E, Priston M, Schorderet DF, Billingsley GD, Girard PO, Lubsen N, Munier FL (1999) *The γ -Crystallins and Human Cataracts: A Puzzle Made Clearer*, Am. J. Hum. Genet. 65: 1261-1267, and Dahm R (2004) *Dying to see*, Sci. Am., 291(4): 52-59). γ -crystallin D and the mutant differ by

three residues, R58H, R36S, and R14C, which were found to increase aggregation (Pande A, Pande J, Asherie N, Lomakin A, Ogun O, King J, Benedek GB (2001) Crystal cataracts: Human genetic cataract caused by protein crystallization, PNAS, 98(11): 6116-6120).

α -synuclein is a 140 residue protein which is found as a main component in Lewy bodies (dense deposits found in the brains of Parkinson's patients that may cause neurodegeneration - Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M (1997) *α -Synuclein in Lewy bodies*, Nature. 388: 839-840).

A β 42 is a small hydrophobic peptide of 42 residues that might play a direct role in the interruption of synaptic function in Alzheimer's, the most common form of nerve pathology (Selkoe DJ (2002) *Alzheimer's disease is a synaptic failure*, Science 298:789-790).

The propensity to form dense β -sheet-like structures, i.e. to aggregate, varies throughout a protein, depending on amino acid composition and sequence.

The aim of the method of the present embodiment was to identify candidate peptide sequences which would allow the speed and amount of aggregate formation to be reduced by blocking the aggregation-prone regions of the target proteins.

IDENTIFICATION OF AGGREGATION REGIONS

So-called 'sensitive regions' for aggregation in parts of the two proteins α -synuclein and A β 42 were predicted by Pawar AP, DuBay KF, Zurdo J, Chiti F, Vendruscolo M, Dobson CM (2005) *Prediction of "aggregation-prone" and*

"aggregation-susceptible" regions in proteins associated with neurodegenerative diseases, J. Mol. Biol. 350: 379-392.

More generally, the above paper proposed an algorithm which allows the calculation of an aggregation propensity profile for a protein and which has been shown to give results which are in close agreement with a wide range of experimental measurements. For any given peptide sequence, it allows the calculation of propensity at every single residue or a propensity smoothed over a window of several amino acids. Table 1 lists the propensities at pH 7.0 for each amino acid separately.

Table 1: *Aggregation propensities at pH 7.0 for each of the 20 naturally occurring amino acids separately.*

Residue	Propensity	Residue	Propensity
Trp	2.92	Gly	-3.96
Phe	2.80	His	-4.31
Cys	1.61	Ser	-5.08
Tyr	1.03	Gln	-6.00
Ile	0.93	Asn	-6.02
Val	0.49	Asp	-9.42
Leu	-0.25	Lys	-9.55
Met	-1.06	Glu	-10.38
Thr	-2.12	Arg	-11.93

Residue	Propensity	Residue	Propensity
Ala	-3.31	Pro	-11.96

Figure 1 shows the aggregation propensity profiles for α -synuclein and A β 42 calculated according to this algorithm (and presented in the above paper). The figure on the left shows the aggregation propensity profile of A β 42 at pH 7. The aggregation profile for the unchanged wild-type A β 42 sequence is plotted as the middle line, along with the maximum and minimum propensity values obtained after testing for any possible mutation at each amino acid position along the sequence. A line at $Z^{prof}_{agg} = 1$ is drawn to aid in identifying aggregation-promoting regions. The same regions derived through experimental processes are shown as shaded regions.

Similarly, the figure on the right shows the amyloid aggregation profile of α -synuclein at pH 7, again including a line at $Z^{prof}_{agg} = 1$ to aid in identifying aggregation-promoting regions. In this figure, the large region of protein thought to be structured in the fibrils is shown by the pale grey shading; the highly amyloidogenic NAC region is shown by the darker grey shading; and the 69-79 region, found to be a particularly amyloidogenic segment within that NAC region, is shown by the hashed lines.

Parts of a protein for which the score crosses a threshold (e.g. $Z^{prof}_{agg} = 1$ in Figure 1) are considered to have the highest propensity for aggregation and are assumed to be the core regions of aggregate and fibril

formation *in vivo*. The predicted core aggregation regions from Figure 1 are used in this embodiment as target sequences for the detection of any interaction partners that might act as inhibitors.

The methodology of the present embodiment will be demonstrated on mutCRYD.

Figure 2 shows the aggregation propensity profile of mutCRYD, averaged over seven residues. As with the aggregation propensity profiles in Figure 1, a line has been added at an aggregation propensity value of 1.0 to assist distinguishing between regions to be considered sensitive to aggregation, and other parts of the protein.

For further searching, residues 34 to 58 were selected. This region has two peaks predicting aggregation hotspots and contains two of the mutations. For a full analysis, all regions with an aggregation propensity larger than 1 would be considered, but the selected short fragment is sufficient to demonstrate the method used. The 24-residue query sequence is SARVDSGCWMLYEQPNYSGLQYFL and will be referred to as mutCRYD34-58.

SEARCHING - OVERVIEW

Although searching through a single file for a sequence is a standard procedure and can be carried out with most text editing programs or command line tools, there might easily be hundreds or thousands of hits in the file for short sequences. Considering each of them by hand, looking for secondary structure information, and then checking the PDB website for more information and using a 3D tool to visualize the structure and looking for inter-

residue interactions in order to extract peptides that are closely linked via hydrogen bonds could take weeks or months for each protein.

Therefore proprietary software was developed to handle the process. The software was developed as a large number of small tools that were then step by step incorporated into a single, comprehensive program called PeptideSearch.

The programming language PERL was chosen for writing PeptideSearch, because all data used was available as plain text files and PERL offers powerful routines to parse through those files and extract and process information contained therein. PERL is also freely available software, prominent with bioinformaticians for these reasons.

Figure 4 presents a flow chart of the software and the methodology of the present embodiment and provides an overview for the detailed explanation of the method which follows.

PeptideSearch relies on calls a number of external programs to extend its functionality. These calls are also shown in Figure 4.

In using the program, the user input is the target sequence plus a number of parameters, and the program ultimately produces a concise summary of the candidate peptides including a three dimensional visualization of the peptides and their interaction partners. The time required to identify possible inhibitors for any protein

was therefore reduced from potentially several weeks to a few hours.

PeptideSearch creates an HTML file called 'result.html' to keep records for each hit. This and all other files created by both the program and the external tools are stored in a new subdirectory. The name of this directory is derived from the current date and time so that the results of all program runs remain available on disk for later usage. While performing a search, PeptideSearch also prints information about hits to the command prompt or console, together with additional status messages. Once the program finishes its run, 'result.html' contains an overview over all hits that were found making it easy to select candidate peptides. The output of the program following a search for residues 1 to 8 of mutCRYD34-58 is presented in Figure 3.

SEARCHING - DETAILED DESCRIPTION

For the present embodiment, the search was based on the entries in the Protein Data Bank (PDB) of the Research Collaboratory for Structural Bioinformatics (RCSB) because this freely accessible online source contains a large number of experimental structures and theoretical models. Therefore, finding all or part of the query sequence within one of the peptide sequences in the PDB gives access to the related structure allowing identification of secondary structure and interaction partners.

The first stage of the search is to search for a target sequence in all of the protein entries in the PDB. This could have been achieved by mirroring the PDB files

locally and parse each of them individually for the sequence of residues. However, this approach would be inefficient in terms of both time and space: as of June 27, 2005, there were 31639 structures in the PDB, many of which as multimers with several chains.

The alternative, which was adopted for this embodiment was to take a single file containing all of the sequence information once and then to search through it in order to detect matches. Such a file is obtainable from the PDB ftp server of the RCSB at ftp://ftp.rcsb.org/pub/pdb/derived_data.

The file, `pdb_seqres.txt`, is a listing of all PDB sequences in FASTA format. Similarly, `ss.txt`, a file containing all secondary structures in the PDB in FASTA format can be found under the same address. The file versions used for this embodiment are dated June 27, 2005.

The secondary structure file presents a first and fast source to perform sequence to secondary structure matching and to detect if a hit is involved in a β -sheet conformation.

Figure 5 shows short excerpts from the two files: the first ten lines from `seq_res.txt` and `ss.txt` respectively. Table 2 below shows the meaning of the abbreviations used in `ss.txt`.

TABLE 2

Abbreviation	Structure element		Abbreviation	Structure element
H	Helix		T	Hydrogen bonded turn
E	Extended beta strand		S	bend
G	310 helix		B	Residue in isolated beta bridge
I	Pi helix			

Cleaning sequence and structure files

The two files referred to above have been derived automatically by the PDB using data from all PDB entries. The secondary structure information in the PDB files has been determined by a number of different programs.

However, the two files are of unequal length. The extracts in Figure 5 show one of the reasons why: the FASTA header lines in the sequence file are longer containing more detailed information.

Considering the origin of the data one would expect that there should be one structure entry for every sequence and vice versa. Also, at first, it seems like the number of lines in the files might be identical making it very convenient to match the content of the two files.

However, neither of these assumptions are true: line numbers do not always match. A PERL script running through the file extracting all FASTA header lines

returned 74560 entries for `pdb_seqres.txt` and 69903 entries for `ss.txt`. There are a number of other problems that needed to be solved before the files could be used as input. For example, usage of IDs was not consistent within and between the two files. The sequence file uses IDs such as `1tsv_`, and distinguishes different chains as `1thl__`, `1thl__1`, `1thl__2`, or as `1pr2_A`, `1pr2_B`, while `ss.txt` uses `1TSV:_`, `1THL:_`, `1THL:__:1`, `1PR2:A`, `1PR2:B`, instead. Also, there are many IDs in the sequence file that do not have a corresponding entry in the secondary structure file, and vice versa: entries such as `1J3W`, `1OG8`, and `1VGS` are contained in `ss.txt` but not in `pdb_seqres.txt`. They have been replaced by IDs `2CVZ`, `2BUH`, and `2CV4` in the Protein Data Bank, which is only accounted for in `pdb_seqres.txt`.

It took a number of PERL scripts to remove all unique entries from both files. The resulting files then contained 68383 matching entries.

A potential problem still remains in that some of the sequences do not match in length. The `PeptideSearch` program was arranged to point out such inconsistencies during run time.

Matching query to sequences

Experimental structures of interest are those in which the amino acid sequence from the query string occurs. This means that one needs to search for the exact matches of the forward string, for `mutCRYD34-58`:

SARVDSGCWMLYEQPNYSGLQYFL

as well as for the inverted sequence, here:

LFYQLGSYNPQEYLMWCGSDVRAS.

It is clearly far less likely to find an exact sequence match in the PDB for long peptides than it is for short ones. Indeed, when searching for matches for a complete protein, it is very likely that only one match will be found: the protein itself.

Even when concentrating on the sensitive region of a protein, one might want to search for hits with stretches of amino acids that are simply too long to give exact hits in the PDB. Since the structure of the mutant of γ -crystallin D is not included in the PDB there is no result for the full 24-residue sequence.

To increase the yield of hits, two further methods were implemented.

First, the target protein sequence was divided into substrings interaction partners were searched for each of these substrings. This allows peptides that bind to part of the sequence to be identified. These can later be tested separately, for example in combination with other peptides, or be engineered into a longer peptide by joining several such peptides together.

In the PeptideSearch program, the user can set a minimal length n and a maximal length m of the search sequence. Following trials, a length of query sequence in the range 5 to 8 residues was found to give a sufficient number of hits while finding interaction partners that were still long enough to still be useful. However, other length substrings may also be used.

The program is arranged to automatically runs a full search for all contiguous substrings of the initial sequence with a length in the given range. The total number of query sequences q searched for a full query sequence of length l is therefore:

$$q = \frac{(l-n+1) \cdot (l-n+2) - (l-m) \cdot (l-m+1)}{2}$$

Second, the program allows the use of regular expressions. This allows variability to be introduced into the search sequence. Accordingly, PeptideSearch allows conservative substitutions to be defined that are taken into account when searching through the amino acid sequence file.

For example, according to Table 1, Gln (Q) and Asn (N) have similar aggregation propensities and therefore one option to increase the number of useful hits would be to consider both in a search. The regular expression of a search string, e.g. QANT would then be [QN]A[QN]T. Other substitutions based on the aggregation properties of the residues can be used in a similar fashion.

The two methods can be combined, so that each possible sub string down to a minimal length is converted into a regular expression which considers the conservative substitutions described above.

Finding secondary structure elements

Data from both pdb_seqres.txt and ss.txt is read once at the start of the program and stored in large arrays. Entries from both arrays are then processed jointly. Since, as noted above, the length of amino acid sequence

and structure do not always match, the line numbers cannot be used as lead. Instead the FASTA header lines serve as guide in order to make sure that the search considers entries that belong together and that the information in both files remains synchronized.

If entries are split over several lines, they are concatenated by removing the line breaks between them. This creates two string variables for each entry, one for the complete amino acid sequence and one for the respective secondary structure. If, at this point, the two strings are of unequal length, then the information given is no longer considered as being reliable. In this case, the program displays a warning to make the user aware of the inconsistency and suggests a manual inspection of the hit.

PERL provides a simple to use routine for searching the sequence string for occurrences of the query sequence, either looking for perfect matches, or by matching regular expressions. If there are any hits then PeptideSearch extracts them from the sequence string and aligns them with the corresponding region of the secondary structure string. This allows a first visual check of how many of the residues in the match are in an extended β -sheet formation.

Since the neighbourhood of a structure might be of interest as well, the program is also arranged to output a number of residues and structure information both to the left and to the right of the match. The size of this window can be set in the program options.

Ideally, this information could simply be used to select all those entries for which the secondary structure file indicates the presence of β -sheets and subsequently only investigate those further. However, with the files used, this would result in many false positives as well as many false negatives. The main reason for this is that the prediction in ss.txt is frequently inaccurate. This has been found when comparing the alignment with the actual structure in the PDB file.

Therefore, it turned out to be better to consider every hit in a sequence regardless of the information in ss.txt. This increases the number of hits that have to be processed further requiring accessing the PDB, but it also ensures that no important candidate peptide is missed.

Retrieving PDB files

Once the query sequence has been detected in one of the entries, more information needs to be obtained and it is necessary to process the actual PDB file. The PDB ID is being extracted from the FASTA header line. A local PDB directory is defined in PeptideSearch.

If the PDB file that belongs to this ID is available in the local directory, be it compressed or uncompressed, then this local copy is used. Otherwise PeptideSearch uses one of its routines to automatically access the mirror of the RCSB Protein Data Bank ftp server at the Cambridge Crystallographic Data Centre (CCBC), <ftp://pdb.ccdc.cam.ac.uk/rcsb/data/structures/divided/pdb/>, and downloads a compressed copy of the PDB file. This

.Z-archive is then extracted via a system call to the program WinRAR.

Processing PDB files

Before opening a PDB file the program checks whether the same PDB ID was used for the preceding hit. This might be the case if there are several hits within the same amino acid sequence, or when the structure in a file is a multimer so that there are analogous hits on each chain. If the ID is the same then the data is still contained within the program's data arrays and can be reused, saving a significant amount of time. Otherwise, the local copy of the PDB file is opened and the data is read to memory.

There are two parts of each file that are of interest. The first are the lines that can be used to identify overlap of the query sequence with β -sheets. These begin with the "SHEET"-tag that show the positions of β -sheets.

The second refers to the "ATOM" entries that give the coordinates for each particle in a molecule. This information allows for the prediction of hydrogen bonds, since knowing which residues actually interact provides important information and gives the researcher more freedom in designing inhibitor peptides. For example, residues whose side chains are not involved in the interaction, might be replaced by others, that provide the peptide with better biochemical properties.

For every strand in a β -sheet there is one "SHEET" line. This contains the index of the first and last residue in the strand. If this strand is not the first in the sheet

then the line also contains the two residues where this and the previous strand have been registered, i.e. indices of a single pair of residues found to be connected by a hydrogen bond. Full information about "SHEET" and "ATOM" entries can be found at http://www.rcsb.org/pdb/docs/format/pdbguide2.2/guide2.2_frame.html.

Extracting the information from those lines and the start and end points of the hit in the amino acid sequence provides a test for overlap: if the start index of the sheet is not larger than the index at the end of the hit and the end index of the sheet is not smaller than the start of the hit then there is overlap, in which case the number of overlapping residues is calculated.

Ideally the number of overlapping residues should not be too small because it defines the length of the potential inhibitor peptide. An inhibitor that consists of only a few residues might not be very efficient, and it will be hard to design a stable peptide with favourable properties. The program enables the user to define a threshold and excludes all hits with overlaps shorter than this threshold from output into 'result.html'.

The β -strand which overlaps with the query sequence and the adjacent strands (either one or two, depending on the position of the first strand in the sheet), are then displayed in an alignment that takes into account strand orientation (parallel or anti-parallel) and registration.

For example, if the peptide sequence is 'ADDYYTATGHWYAT' and the strands run from residues 1 to 4, 6 to 10, and 12 to 14, respectively, in anti-parallel β -sheet formation

with registration at 3 and 7, and 9 and 13, then the alignment results in:

ADDY

HGTAT

YAT

In 'result.html' the residues of the query sequence in this alignment would then be shown in red. If the search was looking, say, for occurrences of 'ATGHW', which would have been found at indices 7 to 11 in the peptide sequence above, then the residues 'HGTA' would be highlighted in the alignment.

The alignment allows rapid screening of hits for those with a large overlap between query sequence and β -sheet. It shows how many and which of the residues form a β -sheet, and consequently how many and which of the residues can be blocked if their interaction partners were to be incorporated into short inhibitor peptides.

Although the above searching methodology provides one route to the identification of candidate peptides, it is not foolproof on the current data available. In particular, the indices of residues found in 'SHEET' lines refer to indices in 'ATOM' lines, but not to the 'SEQRES' records in the same file. The Protein Data Bank assures that references to 'ATOM' records are tested for correctness. The data in 'pdb_seqres.txt', however, was derived from the 'SEQRES' records, and their indices are often not the same. For example, a 'SEQRES' entry might start with MET, while the first 'ATOM' entry is a SER, or

the sequences may be the same, but the first 'ATOM' entry starts with residue index 21, and not 1.

This means that, although the above technique showing alignment might reproduce the relative β -sheet strand positions correctly, the identifier of the residues might be taken from the wrong part of the amino acid sequence. This also means that the identification of an overlap with a β -sheet might have been incorrect in the first place: the query sequence could actually be located at a different position in the structure.

peptideAlign.class

To make sure that such an event can be detected when looking at the summary of this hit later, a further alignment method was developed using the 'ATOM' entries. This allowed an alternative method for deriving candidate peptides, or for a cross-check on the results obtained from the 'SHEET' searching described above.

This alignment method also includes detecting and displaying hydrogen bonds between residues, rendering the alignment much more informative.

The following algorithm was devised for searching in the 'ATOM' data: for all pairs of atoms that are at least three residues apart and are within the interesting part of a β -sheet, calculate the Euclidean distance between them (using the standard formula $d = \sqrt{\Delta x^2 + \Delta y^2 + \Delta z^2}$, where d is the Euclidean distance, and Δx , Δy , and Δz are differences in the respective coordinates).

If the calculated distance is less than 3.075 Angstrom then the indices of this pair of residues are pushed onto a hydrogen bond storage array. The cut-off length was chosen from literature and is large enough to detect most hydrogen bonds between backbone atoms and side chains while it is small enough to keep the number of false positives low.

After completing the prediction, strand and bond information is written to a file called 'bonds.txt'. This file is used as intermediate data storage to share information with another application:

'peptideAlign.class', a Java-based tool that was created for drawing a graphical β -sheet alignment. Although PERL has powerful routines to process large amounts of text, Java offers easier to use graphical functions. Therefore the properties of both programming languages were combined by having 'peptideSearch.pl' use a system call to link out to PeptideAlign. The latter creates a screenshot of an alignment which the PERL program then includes into the overview of the current hit in 'result.html'.

Using graphics facilitates the indication of hydrogen bonds between residues, which can be done by simply drawing lines. PeptideAlign does not directly account for anti-parallel β -sheet formation, but the graphical output does indicate if a strand's orientation should be inverted as in this case the hydrogen bonds cross each other. For example, the blue lines indicating hydrogen bonds in Figure 6 show that orientation of the middle strand needs to be inverted. A further algorithm is used to correctly orientate the strands and shift them

relative to each other in order to minimize the total length of bonds.

PeptideAlign reads peptide and bond information from 'bonds.txt', along with a name for the anticipated output image file. Image file names are of the form hitX.png where X indicates the consecutive number of the hit. The program translates the information in the file into a graphical representation and returns control to peptideSearch. An example output is shown in Figure 7: the file contains path and name of the file to which the screenshot is supposed to be saved, the numbers of atoms and bonds in the file followed by the residue IDs for all atoms and information about which of them are linked by bonds; the graphical representation on the right shows which residues are linked to each other.

Minimalist PDB file

The alignment generated by the 'ATOM' searching is accurate thanks to the curation at the PDB. If this corresponds to the one created by PeptideSearch then the 'SEQRES' record is consistent as well. Otherwise, the user will need to check the graphical overview visually for an overlap. If there is none, a manual check of the PDB file is required to see if there is a different β -sheet that contains part or all of the query sequence.

Note that, at present, it is not possible to create the amino acid sequence anew from the 'ATOM' record and to search this for the occurrence of the query string. This is because residues are often missing from the record. For example, in pdb1p9w.ent residue 108 is followed by residue 121. The gaps can be explained in a number of

ways, for example by insufficient experimental data, low NMR or X-Ray resolution, or highly flexible side chains that result in blurred signals making an exact determination of atom positions impossible. Another explanation is simply that the research providing the data is sometimes only interested in a particular part of a protein, e.g. an active site, and therefore does not provide any prediction of the remaining structure. However, where more complete data is available, such a searching method would be an appropriate stand-alone alternative to the 'SHEET' searching discussed above.

Having found a hit in a β -sheet, it is then possible to see which of the residues interact and build a scaffold for designing candidate peptides. For example, residues that do not interact with the residues in the query sequence might be replaced by other amino acids, allowing a larger range of peptides to be designed and tested.

For example, in the short alignment in Figure 6, SARV interacts with VTY. Hydrogen bonds are predicted between A and V, and V and Y. However, T does not seem to interact with the query sequence at all, so the peptide VXY, could be used as a scaffold for creating candidate peptides, with X being replaceable by different amino acids. Realistically such a scaffold is most likely too short to be effective, hence the preferred searching for peptides with lengths of 5 residues and more.

For each successful hit PeptideSearch creates a new .pdb file containing the coordinates of all atoms involved in the β -sheet. To do this it extracts that part of the complete structure that contains the β -strands with the query sequence fragment and its interaction partners.

The file can be opened with any of the usual 3D viewers such as Rasmol or vmd and permits to efficiently verify predicted hydrogen bonds and spatial orientation of side chains.

Peptide3D.class

To give a preview of the structure in the new .pdb file screenshots are included into the records in 'results.html'. To do so a 3D viewer was required that would allow rendering the molecules, placing them into an informative orientation in space, and taking a screenshot, all without requiring user interaction.

Results.html

Once PeptideSearch has finished running all possible substrings and mutations through all entries in pdb_seqres.txt, it opens a browser window with a system call and presents all the hits it has found in an overview. This overview offers links to the PDB summary page for the PDB ID related to each hit and a link to Peptide3D which is implemented as an applet allowing to view the structure in an 800x600 pixel format.

Results

Running the software with mutCRYD34-58 as input, setting the minimal and maximal substring length to five, allowing no mutations and excluding all hits in which the overlap with a β -sheet is smaller than four resulted in 153 exact matches in pdb_seqres.txt, 47 of which were in β -sheets.

Only eight of these results were longer than three residues and the latter were included in 'result.txt'. In fact, this set actually only gives two distinct hits, because the first two and the last six matches are practically identical since they are from the different chains of a multimer.

The first of those hits refers to the sequence SARVD (mutCRYD34-58 residues 1 to 5) that was found in the Putative Glycine Cleavage System Transcriptional Repressor (PDB ID 1U8S). This is the hit for which the result is presented in Figure 3. The four-residue overlap is depicted in Figure 6.

The second hit was found for the sequence PNYSG (mutCRYD34-58 residues 15 to 20) in Endo-1,4-Beta-Xylanase II. The result summary for this hit from the HTML file is shown in Figure 8.

Figure 9 highlights the two hits in the aggregation propensity profile of mutCRYD34-58. The locations of exact matches near or close to the aggregation hotspots of the two proteins α -synuclein and A β 42 are also shown in the respective profiles in Figure 9. For α -synuclein, the length of sub-strings was set to the range 6 to 7, and for A β 42 it was set to 5.

For mutCRYD, the first hit might not be very effective as a candidate for an aggregation inhibitor as it does not lie within the sensitive region for aggregation. The second hit however, has the potential to block the peptide from initiating formation of aggregates at this site.

For the other two proteins, each of the interaction partners corresponding to the hits shown has the potential to act as aggregation inhibitor. The number of hits for α -synuclein increases strongly when the substring length is set to 5.

The results of the analysis of α -synuclein are the subject of a further patent application by the present applicant.

A series of peptides were designed to interact with regions 61-66 (EQVTN) and 71-76 (VTGVT) of α -synuclein using the software described above.

This analysis identified a peptide consisting of a sequence of D-amino acids which interacts with a region of α -synuclein between residues 61-66 (EQVTN). One suitable peptide comprises or consists of the D-amino acid sequence QYSVLI (ZP-0195 described in Table 3 below). Other suitable peptides may comprise or consist of the D-amino acid sequence QYSVLI with one, two or three amino acid substitutions. For example, a peptide may consist of a D-amino acid sequence selected from the group consisting of: qykvli, qysvpi, qyspli, qypvli, rysvli, qysvli, qytlvli, pysvli, or qysvli.

The peptide may comprise one, two or three additional N terminal residues.

For example, a peptide may comprise or consist of a sequence selected from the group consisting of: ekysvli and drysvli.

The analysis also identified a peptide consisting of a sequence of D-amino acids which interacts with a region

of α -synuclein between residues 71-76 (VTGVT). For example, a peptide may consist of the D-amino acid sequence of hhviva (ZP-0158) or may comprise or consist of the D-amino acid sequence hhviva with one, two or three amino acid substitutions. Preferably, the N-terminal histidine residues are not substituted.

For example, a peptide may comprise or consist of a sequence selected from the group consisting of: hhvvva, hhvlva, hhvkva, hhveva, hpviva, hhvivp, hhvivv, hhvibt, hhvivv, hhvivw, hhtivv, hhtivk, hhtvva, hhtlva, hhtlvv, hhtevv and hhttvv.

For the region 61-65, the peptide Ac-qysvli-NH₂ (ZP-0195) was designed to interact and prevent aggregation. Variations of this sequence were also tested where one or more of the amino acids at any give position was substituted with another and variations were made at the N-terminus such as the addition of an extra amino acid and acetylation (ZP-0195 to ZP-0230).

For the region 71-75 the peptide Ac-hhviva-NH₂ (ZP-0158) was designed to interact and prevent aggregation. Variations of this sequence were also tested where one or more of the amino acids at any give position was substituted with another. All peptides tested were N-terminal acetylated and the 2 histidines at the beginning of the sequence were kept constant in all designs (ZP-0158 to ZP-0194).

All peptides were tested for inhibition of ASYN aggregation in TBS by carrying out aggregation assays with 50 μ M ASYN and 100 μ M inhibitor with 50 mM tris and 150 mM NaCl and 20 μ M Thioflavin T. The reaction volume

was 200 μ L. Each reaction was set up in a 96 well polypropylene plate with ASYN only and buffer only controls. The reactions were incubated at 37C with shaking for 48 hours and aggregation was monitored by reading thioflavin T fluorescence.

The kinetic traces were fitted using Zyentiafit software which fits the data to a Sigmoidal function $f(x)=k+A/(1+\exp(-b(t-t_0)))$ from which the lag time, rate of aggregation and total change in ThT fluorescence may be calculated.

Peptides were ranked according to their effectiveness and table 3 below shows those sequences chosen for further study. The choice was based on the peptide having more than a 20% increase in lag time and/or more than 20% decrease in ThT fluorescence or aggregation rate.

TABLE 3 - Peptide sequences designed to interact with regions 61-66 and 71-76 of ASYN which show effectiveness at preventing ASYN aggregation *in-vitro*.

Zyentia Code	Sequence	% decrease in ThT fluorescence	% decrease in rate of aggregation	% increase in Lag phase
ZP-0158	Ac-hhviva-NH2	15.1	18.4	32.5
ZP-0159	Ac-hhvva-NH2	19.8	18.6	36.6
ZP-0160	Ac-hhvlva-NH2	8.8	10.5	36.5
ZP-0161	Ac-hhvkva-NH2	-5.9	2.3	19.7
ZP-0162	Ac-hhveva-NH2	6.3	6.6	33.4

Zyentia Code	Sequence	% decrease in ThT fluorescence	% decrease in rate of aggregation	% increase in Lag phase
ZP-0164	Ac-hpviva-NH2	3.7	-2.3	43.0
ZP-0168	Ac-hhvivp-NH2	-8.6	-5.4	29.8
ZP-0169	Ac-hhvivv-NH2	-0.5	-13.3	26.1
ZP-0170	Ac-hhvivt-NH2	24.5	29.3	29.4
ZP-0171	Ac-hhvivy-NH2	13.9	13.2	43.6
ZP-0172	Ac-hhvivw-NH2	-1.7	6.9	28.1
ZP-0175	Ac-hhtivv-NH2	21.9	16.8	89.7
ZP-0179	Ac-hhtivk-NH2	0.6	-0.6	30.4
ZP-0180	Ac-hhtvva-NH2	19.8	18.4	30.3
ZP-0181	Ac-hhtlva-NH2	22.8	-1.2	29.4
ZP-0186	Ac-hhtlvv-NH2	30.7	29.7	16.1
ZP-0193	Ac-hhtevy-NH2	8.7	-15.8	31.4
ZP-0194	Ac-hhttvv-NH2	11.6	7.7	38.8
ZP-0202	Ac-qykvli-NH2	53.5	54.5	-28.8
ZP-0204	Ac-qysvpi-NH2	1.4	-5.6	23.6
ZP-0205	Ac-qyspli-NH2	16.6	-11.9	30.6
ZP-0206	Ac-qypvli-NH2	3.3	8.4	25.9
ZP-0207	Ac-qpsvli-NH2	5.5	3.6	29.7
ZP-0212	Ac-rysvli-NH2	51.1	44.9	-14.4

Zyentia Code	Sequence	% decrease in ThT fluorescence	% decrease in rate of aggregation	% increase in Lag phase
ZP-0213	Ac-ekysvli-NH2	25.6	12.9	29.4
ZP-0214	Ac-drysvli-NH2	20.4	4.8	-12.6
ZP-0215	NH3-qysvli-NH2	27.6	17.5	3.1
ZP-0221	NH3-qytlvli-NH2	24.7	22.8	-22.4
ZP-0222	NH3-qykvli-NH2	42.3	34.3	7.7
ZP-0228	NH3-pysvli-NH2	40.8	46.2	38.2
ZP-0229	NH3-qysvlv-NH2	17.8	24.3	33.5

DESIGN OF COMPOUNDS FROM THE RESULTS

Hits identified by the methods or software tools described above may be used as templates to design aggregation inhibitors or stabilisers. Molecular dynamic or other suitable computation methods can be used to test libraries of compounds based on these templates for their affinity to the target sequence.

Computational methods may make use of specific force-fields and energy minimisation routines to a variety of inhibitors based on the template, in order to maximise the interaction between inhibitor and target aggregating polypeptide. (see Das B, Meirovitch H, Navon IM, *Performance of hybrid methods for large-scale unconstrained optimization as applied to models of proteins*, J Comput. Chem. 2003;24:1222-31 and de Bakker

PI, DePristo MA, Burke DF, Blundell TL, *Ab initio construction of polypeptide fragments: Accuracy of loop decoy discrimination by an all-atom statistical potential and the AMBER force field with the Generalized Born solvation model*, Proteins, 2003;51(1):21-40).

Selected compound libraries may be tested *in vitro* in aggregation assays to identify lead compounds that would inhibit the aggregation of the target polypeptides.

Retro-enantio derivatives (reversed C-N sequence and D-amino acids) may be used when the stabiliser/aggregation inhibitor needs to be resistant to other proteases.

The identified stabiliser/aggregation inhibitor may be fused to other proteins/peptides. A protein/peptide fused to a stabiliser/aggregation inhibitor may: act as carriers in order to target delivery to specific areas of the body, specific organs, specific cell types, etc.; facilitate intra-cellular delivery; facilitate blood-brain-barrier translocation; increase the half-life in plasma; and/or interact with another protein or receptor.

CLAIMS

1. A method for predicting potential protein aggregation inhibiting peptide sequences, including the steps of:
 - a) identifying a peptide sequence forming at least part of an aggregation region in a target protein;
 - b) testing whether said peptide sequence forms part of a β -sheet;
 - c) if a positive result is achieved in step b), extracting the adjacent strands of that sheet;
 - d) identifying residues in the adjacent strands to said peptide sequence whose side chains interact with said peptide sequence, those residues forming a potential protein aggregation inhibiting peptide sequence.
2. A method according to claim 1 in which the step of testing is carried out on a plurality of heterologous proteins to said target protein.
3. A method according to claim 2 wherein the step of testing is carried out using a database of protein structures.
4. A method according to claim 3 wherein the step of testing includes the sub-steps of: identifying a group of proteins contained in said database which contain related peptide sequences related to said peptide sequence; and identifying within said group those proteins in which said related peptide sequences form part of a β -sheet.
5. A method according to claim 4 wherein said related peptide sequences include said peptide sequence in both forward and reverse order.

6. A method according to claim 4 or claim 5 wherein said related peptide sequences include said peptide sequence and fragments of said peptide sequence.
7. A method according to any one of claims 4 to 6 wherein said related peptide sequences include sequences containing conservative substitutions of one or more amino acids within said peptide sequence.
8. A method according to claim 7 wherein said conservative substitutions are chosen on the basis of amino acids with aggregation propensities at pH 7.0 of within 0.2 of each other.
9. A method according to any one of claims 4 to 8 wherein the sub-step of identifying includes comparing said related peptide sequences with the residues contained in "SHEET" lines in a PDB file for the protein in question.
10. A method according to any one of claims 4 to 8 wherein the sub-step of identifying includes identifying those residues in said related peptide sequences that form hydrogen bonds with each other.
11. A method according to claim 10 wherein, in order to identify those residues that form hydrogen bonds with each other, the Euclidean distance between each pair of residues which are at least three residues apart is calculated, and a hydrogen bond is assumed to form if that distance is less than 3.075 Angstrom.
12. A method according to claim 11 wherein the Euclidian distances are calculated using "ATOM" entries from the PDB file for the protein in question.

13. A method according to claim 11 or claim 12 further including the step of displaying the identified residue pairs that form hydrogen bonds and the hydrogen bonds between them.

14. A method according to claim 9 or claim 10 wherein the results obtained are compared to results obtained by carrying out a method according to any one of claims 11 to 13 to cross-check the identified residues.

15. A method according to any one of the preceding claims wherein the residues identified in step d) are those residues whose side chains interact with said peptide sequence via hydrogen bonds.

16. A method according to any one of the preceding claims wherein the step of identification uses an aggregation propensity profile.

17. A method according to claim 16 in which the step of identification selects peptide residues with an aggregation propensity greater than 1 in said aggregation propensity profile.

18. A method according to any one of claims 1 to 15 wherein the step of identification is performed experimentally.

19. A method according to any one of the preceding claims further including the step of displaying the residues identified in step d).

20. A method according to claim 19 wherein the step of displaying includes displaying the 3-dimensional arrangement of the identified residues in the β -sheet.

21. A method according to any one of the preceding claims further comprising the step of:

testing whether the residues identified in step d) interact with one or more other proteins.

22. A method according to claim 21 in which the step of testing is carried out on a plurality of heterologous proteins to said target protein.

23. A method according to claim 22 wherein the step of testing is carried out using a database of protein structures.

24. A method according to claim 23 wherein said protein structures are structures which mediate essential cellular processes.

25. A method according to claim 23 or claim 24 wherein the step of testing includes the sub-steps of:
identifying a group of proteins contained in said database which contain related peptide sequences related to said peptide sequence; and identifying within said group those proteins in which said related peptide sequences interact with said identified residues.

26. A method according to any one of the preceding claims wherein the part of the aggregation region identified in step a) is part of a helix, a loop, beta-turn or beta-bulge.

27. A method according to any one of the preceding claims comprising producing a protein aggregation inhibiting peptide comprising the residues identified in step d).

28. A method according to any one of the preceding claims further comprising the steps of:

e) synthesising a peptide library, the members of said peptide library comprising the residues identified in step d), and

f) determining the affinity of the members of said library for the target protein.

29. A method for producing a protein aggregation inhibiting peptide, including the steps of:

a) identifying a peptide sequence forming at least part of an aggregation region in a target protein;

b) testing whether said peptide sequence forms part of a β -sheet;

c) if a positive result is achieved in step b), extracting the adjacent strands of that sheet;

d) identifying residues in the adjacent strands to said peptide sequence whose side chains interact with said peptide sequence, those residues forming a potential protein aggregation inhibiting peptide sequence,

e) synthesising a peptide library, the members of said peptide library comprising the residues identified in step d), and

f) determining the affinity of the members of said library for the target protein.

30. A method according to claim 28 or claim 29 comprising identifying a peptide from said library which displays high affinity for the target protein, relative to controls, as a protein aggregation inhibiting peptide.

31. A method according to claim 30 comprising isolating the peptide identified from said library.

32. A method according to claim 30 comprising synthesising the peptide identified from said library.

33. A method according to claim 27, claim 31 or claim 32 comprising determining the efficacy of said peptide or peptide library in a model of a protein misfolding disease.

34. A method according to claim 33 wherein said model comprises a cell which over-expresses an aggregation-prone protein.

35. A method according to claim 34 wherein the aggregation-prone protein is selected from the group consisting of α -synuclein (either wild type or any of the mutants associated to Parkinson's disease), huntingtin (as well as other proteins with expanded polyglutamine or polyalanine repeats), amyloid beta peptide (A β 42), Prion protein, Islet amyloid polypeptide (hIAPP), Superoxide Dismutase, Tau, alpha-1-antitrypsin and other serpins, lysozyme, vitronectin, crystallins, Fibrinogen alpha chain, Apolipoprotein AI, Cystatin C, Gelsolin, Lactoferrin, Keratoepithelin, Calcitonin, Atrial natriuretic factor, Prolactin, Keratin, Medin (or full-length lactadherin), Immunoglobulin light chains, Transthyretin (TTR), apo-serum amyloid A protein (SAA), Beta2-microglobulin, Immunoglobulin heavy chains, or any other protein associated with any protein misfolding disorder

36. A method according to claim 27, claim 31 or claim 32 comprising determining the ability of said peptide to perform one or more the following:

- i. stabilise a protein against aggregation;

- ii reduce the rate of loss of activity of a protein in storage;
- iii. decrease the aggregation mediated immunogenicity of a protein;
- iv. increase the yields of proteins in *in vitro* translation systems;
- v. increase the stability in solution of a formulation for therapeutic use;
- vi. inhibit one or more cellular processes;
- vii. prevent oligomerisation or multimerisation of a protein.

37. A method of designing an aggregation inhibitor for the treatment of a protein misfolding disease including the steps of: predicting protein aggregation inhibiting peptides according to any one of claims 1 to 22; and using the residue(s) identified in step d) of that prediction to design the aggregation inhibitor.

38. A method of designing a compound for stabilising a protein against aggregation, including the steps of: predicting protein aggregation inhibiting peptides according to any one of claims 1 to 22; and using the residue(s) identified in step d) of that prediction to design a compound for stabilising a protein against aggregation.

39. A method of designing a compound to increase the shelf life of a protein including the steps of: predicting protein aggregation inhibiting peptides according to any one of claims 1 to 22; and using the residue(s) identified in step d) of that prediction to design a compound to increase the shelf life of a protein.

40. A method of designing a compound to decrease the aggregation mediated immunogenicity of a protein including the steps of: predicting protein aggregation inhibiting peptides according to any one of claims 1 to 22; and using the residue(s) identified in step d) of that prediction to design a compound to decrease the aggregation mediated immunogenicity of the protein.

41. A method of designing a compound to increase the yields of proteins in *in vitro* translation systems including the steps of: predicting protein aggregation inhibiting peptides according to any one of claims 1 to 22; and using the residue(s) identified in step d) of that prediction to design a compound to increase the yields of proteins in *in vitro* translation systems.

42. A method of designing compounds for increasing the stability in solution of a formulation for therapeutic use, including the steps of: predicting protein aggregation inhibiting peptides according to any one of claims 1 to 22; and using the residue(s) identified in step d) of that prediction to design compounds with increased stability in solution.

43. A method of determining the effect of a compound on a cellular process, including the steps of: predicting protein aggregation inhibiting peptides according to any one of claims 1 to 22; and screening the residue(s) identified in step d) of that prediction against a collection of protein sequences which mediate said cellular process.

44. A method of designing compounds to be used to prevent oligomerisation or multimerisation of proteins

where such oligomerisation or multimerisation is mediated by an aggregation-prone region, including the steps of: predicting protein aggregation inhibiting peptides according to any one of claims 1 to 22 and using the residue(s) identified in step d) of that prediction to design compounds which will inhibit such oligomerisation or multimerisation by interacting with said aggregation-prone region.

45. A method of designing compounds to be used to inhibit the activity of a target peptide or polypeptide, including the steps of:

- a) identifying a peptide sequence forming at least part of an active region in a target protein;
- b) testing whether said peptide sequence forms part of a β -sheet;
- c) if a positive result is achieved in step b), extracting the adjacent strands of that sheet;
- d) identifying residues in the adjacent strands to said peptide sequence whose side chains interact with said peptide sequence, those residues forming a potential inhibiting peptide sequence; and
- e) using the residue(s) identified in step d) of to design compounds which will inhibit the activity of the target protein.

46. A compound designed according to any one of claims 37 to 45 consisting of L-amino acids.

47. A compound designed according to any one of claims 37 to 45 consisting of D-amino acids.

48. A compound designed according to any one of claims 37 to 45 consisting of a mixture of L- and D-amino acids.

49. A computer program which, when run on a computer, performs the method of any one of claims 1 to 45.

50. A computer data carrier containing a computer program according to claim 49.

51. A computer arranged to perform the method of any one of claims 1 to 45.

52. A computer according to claim 51 wherein the computer is arranged to access external databases containing information on known proteins for use in obtaining the prediction.

Application number / numéro de demande: 2657847

Figures: 3, 4, 8

Pages: _____

Unscannable items
received with this application
(Request original documents in File Prep. Section on the 10th floor)

Documents reçu avec cette demande ne pouvant être balayés
(Commander les documents originaux dans la section de préparation des dossiers au
10^{ème} étage)

FIGURE 1




FIGURE 2




FIGURE 5

First ten lines from pdb_seqres.txt

```

>1pr2_A mol:protein length:239      Purine Nucleoside Phosphorylase

MATPHINAEMGDFADVLM PGDPLRAKYIAETFLEDAREVNNVRGMLGFTGTYKGRKISVMGHGMGIPSCSIYTK

ELITDFGVKKIIRVGSCGAVLPHVKLRD VVIGMGACTDSKVNRIREFKDHDFAAIADFD MVRNAVDAAKALGIDAR

VGNLFSADLFYSPDGEMFDVMEKYGILGVEMEAAGIYGVA AEFGAKALTICTVSDHIRTHEQTTAAERQTTFNDM

IKIALESVLLGDKE

>1pr2_B mol:protein length:239      Purine Nucleoside Phosphorylase

MATPHINAEMGDFADVLM PGDPLRAKYIAETFLEDAREVNNVRGMLGFTGTYKGRKISVMGHGMGIPSCSIYTK

ELITDFGVKKIIRVGSCGAVLPHVKLRD VVIGMGACTDSKVNRIREFKDHDFAAIADFD MVRNAVDAAKALGIDAR

VGNLFSADLFYSPDGEMFDVMEKYGILGVEMEAAGIYGVA AEFGAKALTICTVSDHIRTHEQTTAAERQTTFNDM

IKIALESVLLGDKE

```

First ten lines from ss.txt:

```

>1PR2:A

  BTTB   TTSS S EEEEE S T H H H H H H H H H T BS EE B GGG  EEEEE E T EEEEE   S S H H H H H H H H H

H H H H S   EEEEE EEEEE S T T T T T EEEEE EEEEE S H H H H T T S   B   H H H H H H H H H H H H T T   E E

EEEEEE S  S S S  T H H H H H H H T T   E E S S H H H H H H H H H T T EEEEE E E T T S   H H H H H H H H H H

H H H H H H H H H H

>1PR2:B

  SS     TTSS S EEEEE S S H H H H H H H H H BS EE B GGG  EEEEE E T EEEEE   S S H H H H H H H H H

H H H H S   EEEEE EEEEE S T T T T T EEEEE EEEEE S H H H H T T S   B   H H H H H H H H H H H H T T   E

EEEEEE S  S S S S T H H H H H H H T T   E E S S H H H H H H H H H T T EEEEE E E T T T   H H H H H H H H H H

H H H H H H H H H H

```

FIGURE 6

Predicted hydrogen bonds





FIGURE 7

OUTPUT TO 2005_08_19_14h11m01s/images/hit38.png	Predicted hydrogen bonds
NUMATOMS 9	
NUMBONDS 4	
RESID THR 188	
RESID VAL 189	
RESID SER 190	
RESID ILE 60	
RESID ASN 61	
BOND ASN 61SER 188	
RESID PHE 62	
RESID SER 63	
BOND SER 63THR 190	
RESID GLY 148	
BOND GLY 148PHE 61	
RESID SER 149	
BOND SER 149ASN 62	

FIGURE 9



Flow chart of peptide search process

